U.S. markets closed

Calithera Biosciences, Inc. (CALA)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1750-0.0050 (-2.78%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.1800
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range0.1750 - 0.2400
52 Week Range0.1100 - 13.3800
Avg. Volume288,580
Market Cap851,420
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-28.7780
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CALA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Calithera Biosciences, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Fair Value
    Economic Moat
    23 hours agoMorningstar
View more
  • American City Business Journals

    Biotech company Calithera plans its own death. Will others follow?

    The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.

  • Benzinga

    Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution

    Calithera Biosciences Inc (NASDAQ: CALA) announced that its Board of Directors has determined that it is in the best interests of its shareholders to dissolve the company and liquidate its assets. To reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. The company intends to call its shareholders for a special meeting in the

  • GlobeNewswire

    Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all